The results showed that the treatment of overweight/obese patients without diabetes with glucagon-like 1 peptide agonists including liraglutide, exenatide, and semaglutide significantly achieved greater weight loss than placebo (-6.82 vs -3.96) and metformin (-5.87, -5.05). The analysis demonstrated that semaglutide displayed the most obvious anti-obesity effect with respect to weight loss, the reduction of body mass index, and waist circumference. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.